Reviews Omniscan


No reviews yet.

Omniscan Drug Description
OMNISCAN™
(gadodiamide) Injection for Intravenons Use

WARNING: NOT FOR INTRATHECAL USE and NEPHROGENIC SYSTEMIC
FIBROSIS (NSF)
NOT FOR INTRATHECAL USE
Inadvertent intrathecal use of OMNISCAN has caused convulsions, coma, sensory
and motor neurologic deficits [see Warnings and PRECAUTIONS].
NSF
Gadolinium-based contrast agents increase the risk for NSF in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle, and internal organs. Screen
all patients for renal dysfunction by obtaining a history and laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see Warnings and PRECAUTIONS].

DRUG DESCRIPTION
OMNISCAN (gadodiamide) Injection is the formulation of the gadolinium complex
of diethylenetriamine pentaacetic acid bismethylamide, and is an injectable,
nonionic extracellular enhancing agent for magnetic resonance imaging. OMNISCAN
is administered by intravenous injection. OMNISCAN is provided as a sterile,
clear, colorless to slightly yellow, aqueous solution. Each 1 mL contains 287
mg gadodiamide and 12 mg caldiamide sodium in Water for Injection. The pH is
adjusted between 5.5 and 7.0 with hydrochloric acid and/or sodium hydroxide.
OMNISCAN contains no antimicrobial preservative. OMNISCAN is a 0.5 mol/L solution
of aqua[5,8-bis(carboxymethyl)-ll-[2-(methylamino)-2-oxoethyl]-3-oxo- 2,5,8,1
l-tetraazatridecan-13-oato (3-)-N5, N8, N11, O3, O5, O8, O11, O13] gadolinium
hydrate, with a molecular weight of 573.66 (anhydrous), an empirical formula
of C16H28GdN5O9•xH2O2,
and the following structural formula:







Pertinent physicochemical data for OMNISCAN are noted below:



PARAMETER


Osmolality (mOsmol/kg water)
@37°C
789


Viscosity (cP)
@20°C
2


@37°C
1.4


Density (g/mL)
@25°C
1.14


Specific gravity
@25°C
1.15



OMNISCAN has an osmolality approximately 2.8 times that of plasma at 37°C and is hypertonic under conditions of use.
Last reviewed on RxList: 1/15/2008




Omniscan Drug Description
OMNISCAN™
(gadodiamide) Injection for Intravenons Use

WARNING: NOT FOR INTRATHECAL USE and NEPHROGENIC SYSTEMIC
FIBROSIS (NSF)
NOT FOR INTRATHECAL USE
Inadvertent intrathecal use of OMNISCAN has caused convulsions, coma, sensory
and motor neurologic deficits [see Warnings and PRECAUTIONS].
NSF
Gadolinium-based contrast agents increase the risk for NSF in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle, and internal organs. Screen
all patients for renal dysfunction by obtaining a history and laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see Warnings and PRECAUTIONS].

DRUG DESCRIPTION
OMNISCAN (gadodiamide) Injection is the formulation of the gadolinium complex
of diethylenetriamine pentaacetic acid bismethylamide, and is an injectable,
nonionic extracellular enhancing agent for magnetic resonance imaging. OMNISCAN
is administered by intravenous injection. OMNISCAN is provided as a sterile,
clear, colorless to slightly yellow, aqueous solution. Each 1 mL contains 287
mg gadodiamide and 12 mg caldiamide sodium in Water for Injection. The pH is
adjusted between 5.5 and 7.0 with hydrochloric acid and/or sodium hydroxide.
OMNISCAN contains no antimicrobial preservative. OMNISCAN is a 0.5 mol/L solution
of aqua[5,8-bis(carboxymethyl)-ll-[2-(methylamino)-2-oxoethyl]-3-oxo- 2,5,8,1
l-tetraazatridecan-13-oato (3-)-N5, N8, N11, O3, O5, O8, O11, O13] gadolinium
hydrate, with a molecular weight of 573.66 (anhydrous), an empirical formula
of C16H28GdN5O9•xH2O2,
and the following structural formula:







Pertinent physicochemical data for OMNISCAN are noted below:



PARAMETER


Osmolality (mOsmol/kg water)
@37°C
789


Viscosity (cP)
@20°C
2


@37°C
1.4


Density (g/mL)
@25°C
1.14


Specific gravity
@25°C
1.15



OMNISCAN has an osmolality approximately 2.8 times that of plasma at 37°C and is hypertonic under conditions of use.
Last reviewed on RxList: 1/15/2008




Omniscan Drug Description
OMNISCAN™
(gadodiamide) Injection for Intravenons Use

WARNING: NOT FOR INTRATHECAL USE and NEPHROGENIC SYSTEMIC
FIBROSIS (NSF)
NOT FOR INTRATHECAL USE
Inadvertent intrathecal use of OMNISCAN has caused convulsions, coma, sensory
and motor neurologic deficits [see Warnings and PRECAUTIONS].
NSF
Gadolinium-based contrast agents increase the risk for NSF in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle, and internal organs. Screen
all patients for renal dysfunction by obtaining a history and laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see Warnings and PRECAUTIONS].

DRUG DESCRIPTION
OMNISCAN (gadodiamide) Injection is the formulation of the gadolinium complex
of diethylenetriamine pentaacetic acid bismethylamide, and is an injectable,
nonionic extracellular enhancing agent for magnetic resonance imaging. OMNISCAN
is administered by intravenous injection. OMNISCAN is provided as a sterile,
clear, colorless to slightly yellow, aqueous solution. Each 1 mL contains 287
mg gadodiamide and 12 mg caldiamide sodium in Water for Injection. The pH is
adjusted between 5.5 and 7.0 with hydrochloric acid and/or sodium hydroxide.
OMNISCAN contains no antimicrobial preservative. OMNISCAN is a 0.5 mol/L solution
of aqua[5,8-bis(carboxymethyl)-ll-[2-(methylamino)-2-oxoethyl]-3-oxo- 2,5,8,1
l-tetraazatridecan-13-oato (3-)-N5, N8, N11, O3, O5, O8, O11, O13] gadolinium
hydrate, with a molecular weight of 573.66 (anhydrous), an empirical formula
of C16H28GdN5O9•xH2O2,
and the following structural formula:







Pertinent physicochemical data for OMNISCAN are noted below:



PARAMETER


Osmolality (mOsmol/kg water)
@37°C
789


Viscosity (cP)
@20°C
2


@37°C
1.4


Density (g/mL)
@25°C
1.14


Specific gravity
@25°C
1.15



OMNISCAN has an osmolality approximately 2.8 times that of plasma at 37°C and is hypertonic under conditions of use.
Last reviewed on RxList: 1/15/2008




Omniscan Drug Description
OMNISCAN™
(gadodiamide) Injection for Intravenons Use

WARNING: NOT FOR INTRATHECAL USE and NEPHROGENIC SYSTEMIC
FIBROSIS (NSF)
NOT FOR INTRATHECAL USE
Inadvertent intrathecal use of OMNISCAN has caused convulsions, coma, sensory
and motor neurologic deficits [see Warnings and PRECAUTIONS].
NSF
Gadolinium-based contrast agents increase the risk for NSF in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle, and internal organs. Screen
all patients for renal dysfunction by obtaining a history and laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see Warnings and PRECAUTIONS].

DRUG DESCRIPTION
OMNISCAN (gadodiamide) Injection is the formulation of the gadolinium complex
of diethylenetriamine pentaacetic acid bismethylamide, and is an injectable,
nonionic extracellular enhancing agent for magnetic resonance imaging. OMNISCAN
is administered by intravenous injection. OMNISCAN is provided as a sterile,
clear, colorless to slightly yellow, aqueous solution. Each 1 mL contains 287
mg gadodiamide and 12 mg caldiamide sodium in Water for Injection. The pH is
adjusted between 5.5 and 7.0 with hydrochloric acid and/or sodium hydroxide.
OMNISCAN contains no antimicrobial preservative. OMNISCAN is a 0.5 mol/L solution
of aqua[5,8-bis(carboxymethyl)-ll-[2-(methylamino)-2-oxoethyl]-3-oxo- 2,5,8,1
l-tetraazatridecan-13-oato (3-)-N5, N8, N11, O3, O5, O8, O11, O13] gadolinium
hydrate, with a molecular weight of 573.66 (anhydrous), an empirical formula
of C16H28GdN5O9•xH2O2,
and the following structural formula:







Pertinent physicochemical data for OMNISCAN are noted below:



PARAMETER


Osmolality (mOsmol/kg water)
@37°C
789


Viscosity (cP)
@20°C
2


@37°C
1.4


Density (g/mL)
@25°C
1.14


Specific gravity
@25°C
1.15



OMNISCAN has an osmolality approximately 2.8 times that of plasma at 37°C and is hypertonic under conditions of use.
Last reviewed on RxList: 1/15/2008




Omniscan Drug Description
OMNISCAN™
(gadodiamide) Injection for Intravenons Use

WARNING: NOT FOR INTRATHECAL USE and NEPHROGENIC SYSTEMIC
FIBROSIS (NSF)
NOT FOR INTRATHECAL USE
Inadvertent intrathecal use of OMNISCAN has caused convulsions, coma, sensory
and motor neurologic deficits [see Warnings and PRECAUTIONS].
NSF
Gadolinium-based contrast agents increase the risk for NSF in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m2), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle, and internal organs. Screen
all patients for renal dysfunction by obtaining a history and laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see Warnings and PRECAUTIONS].

DRUG DESCRIPTION
OMNISCAN (gadodiamide) Injection is the formulation of the gadolinium complex
of diethylenetriamine pentaacetic acid bismethylamide, and is an injectable,
nonionic extracellular enhancing agent for magnetic resonance imaging. OMNISCAN
is administered by intravenous injection. OMNISCAN is provided as a sterile,
clear, colorless to slightly yellow, aqueous solution. Each 1 mL contains 287
mg gadodiamide and 12 mg caldiamide sodium in Water for Injection. The pH is
adjusted between 5.5 and 7.0 with hydrochloric acid and/or sodium hydroxide.
OMNISCAN contains no antimicrobial preservative. OMNISCAN is a 0.5 mol/L solution
of aqua[5,8-bis(carboxymethyl)-ll-[2-(methylamino)-2-oxoethyl]-3-oxo- 2,5,8,1
l-tetraazatridecan-13-oato (3-)-N5, N8, N11, O3, O5, O8, O11, O13] gadolinium
hydrate, with a molecular weight of 573.66 (anhydrous), an empirical formula
of C16H28GdN5O9•xH2O2,
and the following structural formula:







Pertinent physicochemical data for OMNISCAN are noted below:



PARAMETER


Osmolality (mOsmol/kg water)
@37°C
789


Viscosity (cP)
@20°C
2


@37°C
1.4


Density (g/mL)
@25°C
1.14


Specific gravity
@25°C
1.15



OMNISCAN has an osmolality approximately 2.8 times that of plasma at 37°C and is hypertonic under conditions of use.
Last reviewed on RxList: 1/15/2008





Other reviews about Omniscan on wordpress

Please take this survey....Thank You
  by turbospinecho
If you took my earlier survery thanks but I had to start this new one, so please retake it. I appreciate your patients with me. If you are […]


FDA and GE Blamed for MRI Deaths
  by pochp
GE's Omniscan dye blamed for disease and deaths: 'In May 2006, Danish medical regulators came to GE with troubling findings. Twenty-five patients with weak kidneys had developed NSF, a […]


New evidence shows Omniscan, optimark and Magnevist can cuause NSF more frequently than other Gadolinium agents
  by turbospinecho
A panel of medical experts has found that several gadolinium contrast dyes – OptiMark, Omniscan and Magnevist – appear to carry more risk of nephrogenic systemic fibrosis (NSF) than […]


Drug giant General Electric uses libel law to gag doctor
  by steve virgin
General Electric, one of the world’s biggest corporations, is using the London libel courts to gag a senior radiologist after he raised the alarm over the potentially fatal […]


Obama's Partner General Electric: New Drug From G.E. Healthcare A Medical 'Nightmare' -Omniscan
  by Volubrjotr
[caption id="attachment_15417" align="alignleft" width="224" caption="General Electric's Deadly Omniscan Drug"][/caption] General Electric, one of the world’s biggest corporations, is using the London libel courts to gag a senior radiologist after […]


There is tourism, and there is libel tourism
  by Ellen
[caption id="attachment_783" align="alignleft" width="300" caption="Lord Phillips, President of the Supreme Court of the United Kingdom"][/caption] Is this not an important principle? There is such a thing as Corporate Social Responsibility (CSR) […]


GE and Muzzled Radiologist End Libel Case
  by Editors
MRI Drug Omniscan Implicated in UK By Staff Reporters General Electric Healthcare has settled its libel lawsuit against Dr. Henrik Thomsen, the Danish radiologist who raised questions about the […]


GE Violated Danish Drug Reporting Law
  by Editors
In the Omniscan Case By Jeff Gerth, ProPublica - June 17, 2010 5:59 pm EDT   General Electric's health care unit failed to promptly and completely inform regulators about a patient […]


Afghanistan Opium Or Lithium : British Monarchy Brought Down China With Opium : Now They're Doing The Same With The United States! 'DETAILED'
  by Volubrjotr
[youtube=http://www.youtube.com/watch?v=Z-9iNVoeghI&feature=related] Dope inc. : Britain's opium war against the U.S by Konstandinos Kalimtgis also by David Goldman and Jeffrey Steinberg 1978 Dedication Acknowledgments Introduction Part I: History Introduction Britain's First Opium Wars Palmerston's Fifth […]


NSF and gadolinium contrast in MR examinations: FDA updates warning labels
  by Maribel
The U.S. Food and Drug Administration has just updated the regulations regarding warning labels on gadolinium-based MRI contrast agents, due to the risk of NSF. From now on, Magnevist, […]



Other reviews about Omniscan on web:

Learn about the prescription medication Omniscan (Gadodiamide), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Omniscan (Gadodiamide) Drug Information: Uses, Side Effects, Drug ...


Gadodiamide is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan. Gadodiamide - Wikipedia, the free encyclopedia


Provides instrumentation and consulting for measurement of surface roughness, waviness and shape; layer thickness and optical properties ranging from the sub-nanometer to the ... Omniscan - Innovative Measurement Solutions


Accurate, FDA approved Omniscan information for healthcare professionals and patients - brought to you by Drugs.com. Omniscan Official FDA information, side effects and uses.


With OmniScan, you can scan the entire market for virtually any fundamental or technical condition, generating fresh, pre-qualified lists each day. OmniScan - OmniTrader's trading system subscription service ...


Phased Array Inspection Phased Array Technology Phased array technology enables the generation of an ultrasonic beam where parameters such as angle, focal ... OmniScan MX PA


Omniscan, gadodiamide, side effects could cause Nephrogenic Systemic Fibrosis for those with kidney problems. Free lawsuit evaluations. Omniscan Lawsuits - GE Healthcare Gadodiamide Settlement Lawyers ...


Omniscan and Gadodiamide Information. News and Information on Omniscan, Attorneys and Lawyers at LegalView.info Omniscan and Gadodiamide - Attorney, Lawsuit, Law Suit, Case ...


With hundreds of units being used throughout the world, the OmniScan MX is Olympus most successful portable and modular phased array and eddy current array test instrument. OmniScan MX


Our firm, and our affiliated firms are accepting cases of NSF and NFD and we would be happy to discuss any concerns you may have, if you or a loved one is suffering this ... Omniscan® Brent Coon & Associates Asbestos Exposure





Featured Reviews

Reviews Protonix

Protonix Drug Description PROTONIX (pantoprazole sodium) Delayed-Release Tablets PROTONIX (pantoprazole sodium) for Delayed-Release Oral Suspension DRUG DESCRIPTION What are the possible side effects of pantoprazole (Protonix)? Get...
Read More  |  Review This
Reviews Fentanyl Citrate

Actiq Drug Description ACTIQ® (fentanyl citrate) Oral Transmucosal Lozenge WARNING IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR ABUSE Reports of serious adverse events, including deaths in patients treated ...
Read More  |  Review This
Reviews Diphenoxylate and Atropine

Lomotil Drug Description Lomotil® CV (diphenoxylate hydrochloride and atropine sulfate) Tablets, USP (diphenoxylate hydrochloride and atropine sulfate liquid) Oral Solution, USP DRUG DESCRIPTION What are the possible side effects...
Read More  |  Review This
Reviews Metronidazole Injection

Metronidazole Injection Drug Description Metronidazole (metronidazole) Injection Sterile For Intravenous Infusion Only. WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS). Its use,...
Read More  |  Review This
Reviews Amiodarone HCl Injection

Amiodarone HCl Injection Drug Description Amiodarone HCl Injection For Intravenous Use Only DRUG DESCRIPTION Amiodarone HCl Injection contains amiodarone HCl (C25H29I2NO3•HCl), a class III antiarrhythmic drug. Amiodarone HCl is...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....